Skip to main content
ConductScienceScienceDex

Badie, Behnam

From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.

FY2023 NIH rank #3,423
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2019 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2023

Linked Award Amount
$2.1M
Full award amounts, FY2023
Award Records
3
Records listing this PI
Award-Linked Rank
#3,423
By linked amount among FY2023 PIs
Earliest Year Loaded
2019
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Badie, Behnam. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2023 award records by amount

NIH award records listing Badie, Behnam as a PI. Multi-PI records show the full award amount for context.

  • 5U19CA264512-03U19Contact PI
    Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability
    Beckman Research Institute/City of Hope
    $917.7K
    award amount
  • 5R01CA254271-04R01Contact PI
    Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma
    Beckman Research Institute/City of Hope
    $734.2K
    award amount
  • 5R01CA236500-05R01Contact PI
    Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma
    Beckman Research Institute/City of Hope
    $469.6K
    award amount

Award organization

Organizations that administered FY2023 awards listing Badie, Behnam as a PI.

FY2023 award administered by Beckman Research Institute/City of Hope (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2019
    First NIH Award
    Beckman Research Institute/City of Hope
  2. 2019
    $500K Cumulative Funding
  3. 2020
    $1M Cumulative Funding
  4. 2020
    Entered Top 50% Nationally
    Ranked #6485
  5. 2020
    R01 Grant Holder
  6. 2021
    $2M Cumulative Funding
  7. 2021
    Entered Top 25% Nationally
    Ranked #2494
  8. 2022
    $5M Cumulative Funding

Explore further

Find collaborators for Badie, Behnam

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →